• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

    8/2/24 6:51:55 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLN alert in real time by email
    SC 13G/A 1 d780589dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 2)

     

     

    Silence Therapeutics plc

    (Name of Issuer)

    Ordinary Shares, nominal value £0.05 per share

    (Title of Class of Securities)

    82686Q101**

    (CUSIP Number)

    July 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **

    This CUSIP number applies to the Issuer’s American Depositary Shares, each representing three ordinary shares of the Issuer.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities, L.P.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    8,338,857*

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    8,338,857*

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,338,857*

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    *

    Invus Public Equities, L.P. holds an aggregate of 2,779,619 American Depositary Shares (“ADSs”), each of which ADS represents three ordinary shares, nominal value £0.05 per share, totaling 8,338,857 ordinary shares of the Issuer.

     

    2


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities Advisors, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    8,338,857*

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    8,338,857*

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,338,857*

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    Invus Public Equities, L.P. holds an aggregate of 2,779,619 American Depositary Shares (“ADSs”), each of which ADS represents three ordinary shares, nominal value £0.05 per share, totaling 8,338,857 ordinary shares of the Issuer.

     

    3


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Global Management, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    8,338,857*

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    8,338,857*

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,338,857*

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    Invus Public Equities, L.P. holds an aggregate of 2,779,619 American Depositary Shares (“ADSs”), each of which ADS represents three ordinary shares, nominal value £0.05 per share, totaling 8,338,857 ordinary shares of the Issuer.

     

    4


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Siren, L.L.C.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    8,338,857*

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    8,338,857*

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,338,857*

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    Invus Public Equities, L.P. holds an aggregate of 2,779,619 American Depositary Shares (“ADSs”), each of which ADS represents three ordinary shares, nominal value £0.05 per share, totaling 8,338,857 ordinary shares of the Issuer.

     

    5


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Raymond Debbane

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Panama

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    8,338,857*

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    8,338,857*

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,338,857*

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *

    Invus Public Equities, L.P. holds an aggregate of 2,779,619 American Depositary Shares (“ADSs”), each of which ADS represents three ordinary shares, nominal value £0.05 per share, totaling 8,338,857 ordinary shares of the Issuer.

     

    6


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International S.C.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    7


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International Management S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    8


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal Group S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    9


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Westend S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    10


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Stichting Administratiekantoor Westend

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    11


    CUSIP No. 82686Q101

     

    1   

    NAMES OF REPORTING PERSONS

     

    Mr. Amaury Wittouck

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Belgium

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    12


    Explanatory Note

    On July 25, 2024, in connection with a reorganization (the “Reorganization”), Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors (each defined below). Siren (defined below) is the managing member of Global Management and Mr. Raymond Debbane is the managing member of Siren. Accordingly, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Amaury Wittouck (each defined below and together, the “Artal Parties”) are no longer deemed to beneficially own the Shares directly held by Invus Public Equities (defined below). This Schedule 13G reports beneficial ownership as of July 25, 2024, immediately following the Reorganization, and reflects an exit filing by the Artal Parties and an initial filing on Schedule 13G by Global Management, Siren and Mr. Debbane. See Item 4.

     

    Item 1(a).

    Name of Issuer:

    Silence Therapeutics plc (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    72 Hammersmith Road, London W14 8TH

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Invus Global Management, LLC (“Global Management”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iv) Siren, L.L.C. (“Siren”)

    c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (v) Raymond Debbane

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Panama

    (vi) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (vii) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (viii) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

     

    13


    (ix) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (x) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (xi) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Ordinary Shares, nominal value £0.05 per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    The CUSIP Number is 82686Q101. This CUSIP applies to the American Depositary Shares (“ADSs”), evidenced by American Depositary Receipts, each representing three Shares. No CUSIP has been assigned to the Shares.

     

    Item  3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item  4.

    Ownership.

    (a) Amount beneficially owned:

    As of July 25, 2024, following the Reorganization whereby Global Management became the managing member of Invus PE Advisors, Invus Public Equities beneficially held 8,338,857 Shares represented by an aggregate of 2,779,619 American Depositary Shares directly held by Invus Public Equities. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and, accordingly, may be deemed to beneficially own the Shares that Siren may be deemed to beneficially own.

    (b) Percent of class:

    As of July 25, 2024, following the Reorganization, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 139,979,812 Shares outstanding as of April 15, 2024 based on information set forth in the Issuer’s Prospectus filed on Form 424B3, filed with the Securities and Exchange Commission on May 14, 2024.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Global Management, Siren and Mr. Debbane has:

     

      (i)

    Sole power to vote or to direct the vote:

    8,338,857

     

    14


      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    8,338,857

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

    As of July 25, 2024, following the Reorganization, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck are no longer deemed to beneficially own any Shares.

     

    Item  5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    On July 25, 2024, in connection with the Reorganization, Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors. Accordingly, the Geneva branch of Artal International, Artal International Management, Artal Group, Westend, Stichting and Mr. Wittouck are no longer deemed to beneficially own the Shares directly held by Invus Public Equities and have ceased to be Reporting Persons.

     

    Item  6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item  7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item  8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item  9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    15


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 2, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS,
    LLC, its general partner
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS GLOBAL MANAGEMENT, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    SIREN, L.L.C.
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    MR. RAYMOND DEBBANE
    By:   /s/ Raymond Debbane
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL
    MANAGEMENT S.A., its managing partner
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director


    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:   /s/ Amaury Wittouck
    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    /s/ Amaury Wittouck


    EXHIBIT INDEX

     

    Exhibit
    Number
      

    Title

    1.    Joint Filing Agreement
    Get the next $SLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLN

    DatePrice TargetRatingAnalyst
    2/11/2025$6.00Sell
    Goldman
    12/2/2024Outperform
    BMO Capital Markets
    9/3/2024$40.00Buy
    Jefferies
    1/31/2024$67.00Outperform
    BMO Capital Markets
    5/8/2023$20.00Overweight
    Morgan Stanley
    12/9/2022$18.00Equal-Weight
    Morgan Stanley
    3/31/2022$33.00Buy
    Chardan Capital Markets
    More analyst ratings

    $SLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are a

      5/8/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineer

      3/5/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/21/25 6:49:38 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mcinerney Timothy

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/20/25 4:14:11 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Mcinerney Timothy

      3 - Silence Therapeutics plc (0001479615) (Issuer)

      5/20/25 4:12:58 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Silence Therapeutics with a new price target

      Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

      2/11/25 7:12:20 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets reiterated coverage on Silence Therapeutics

      BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

      12/2/24 10:09:42 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Silence Therapeutics with a new price target

      Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

      9/3/24 8:14:09 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Financials

    Live finance-specific insights

    See more
    • Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

      2/27/25 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

      2/13/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

      Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

      6/27/24 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Silence Therapeutics Plc

      DEF 14A - Silence Therapeutics plc (0001479615) (Filer)

      5/16/25 6:05:34 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Silence Therapeutics Plc

      SCHEDULE 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      5/15/25 9:02:25 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Silence Therapeutics Plc

      10-Q - Silence Therapeutics plc (0001479615) (Filer)

      5/8/25 8:35:12 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 1:13:14 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 9:44:01 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/12/24 4:31:49 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Leadership Updates

    Live Leadership Updates

    See more
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

      Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

      4/29/24 8:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

      Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut

      3/28/23 7:05:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care